Clinical Trials Logo

New Onset Glaucoma clinical trials

View clinical trials related to New Onset Glaucoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT00727038 Withdrawn - Glaucoma Clinical Trials

Lucentis for New Onset Neovascular Glaucoma

NVG
Start date: January 4, 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Neovascular glaucoma is a potentially debilitating disease of the eye. Vascular eye disease such as diabetes and vein occlusions can cause the retina to release factors that promote the growth of abnormal blood vessels. These abnormal vessels can grow in the drainage mechanism of the eye causing pressure in the eye to markedly increase. This can potentially cause irreversible damage to the optic nerve from glaucoma leading to permanent blindness and painful eyes. Conventional treatments including laser and freezing therapy take weeks to cause regression in abnormal blood vessel growth. This delay often results in permanent vision loss and pain. New medications targeted at more immediately reducing blood vessel growth may aid in the treatment of this disease.